4.0 Article

National Patterns in Antidepressant Medication Treatment

期刊

ARCHIVES OF GENERAL PSYCHIATRY
卷 66, 期 8, 页码 848-856

出版社

AMER MEDICAL ASSOC
DOI: 10.1001/archgenpsychiatry.2009.81

关键词

-

资金

  1. National Institutes of Health (NIH)
  2. Agency for Healthcare Research and Quality
  3. American Foundation for Suicide Prevention
  4. National Association for Research on Schizophrenia and Affective Disorders
  5. New York State Office of Mental Health
  6. AstraZeneca, PLC
  7. Bristol-Myers Squibb Co
  8. Eli Lilly and Company
  9. Ortho-McNeil Janssen Scientific Affairs, LLC
  10. NIH
  11. National Patent Safety Foundation
  12. Bristol-Myers Squibb Co
  13. AstraZeneca, PLC
  14. Agency for Healthcare Research and Quality [U18-HS016097]
  15. National Alliance for Research on Schizophrenia and Depression

向作者/读者索取更多资源

Context: Antidepressants have recently become the most commonly prescribed class of medications in the United States. Objective: To compare sociodemographic and clinical patterns of antidepressant medication treatment in the United States between 1996 and 2005. Design: Analysis of antidepressant use data from the 1996 (n=18 993) and 2005 (n=28 445) Medical Expenditure Panel Surveys. Setting: Households in the United States. Participants: Respondents aged 6 years or older who reported receiving at least 1 antidepressant prescription during that calendar year. Main Outcome Measures: Rate of antidepressant use and adjusted rate ratios (ARRs) of year effect on rate of antidepressant use adjusted for age, sex, race/ethnicity, annual family income, self-perceived mental health, and insurance status. Results: The rate of antidepressant treatment increased from 5.84% (95% confidence interval [CI], 5.47-6.23) in 1996 to 10.12% (9.58-10.69) in 2005 (ARR, 1.68; 95% CI, 1.55-1.81), or from 13.3 to 27.0 million persons. Significant increases in antidepressant use were evident across all sociodemographic groups examined, except African Americans (ARR, 1.13; 95% CI, 0.89-1.44), who had comparatively low rates of use in both years (1996, 3.61%; 2005, 4.51%). Although antidepressant treatment increased for Hispanics (ARR, 1.75; 95% CI, 1.60-1.90), it remained comparatively low (1996, 3.72%; 2005, 5.21%). Among antidepressant users, the percentage of patients treated for depression did not significantly change (1996, 26.25% vs 2005, 26.85%; ARR, 0.95; 95% CI, 0.83-1.07), although the percentage of patients receiving antipsychotic medications (5.46% vs 8.86%; ARR, 1.77; 95% CI, 1.31-2.38) increased and those undergoing psychotherapy declined (31.50% vs 19.87%; ARR, 0.65; 95% CI, 0.56-0.72). Conclusions: From 1996 to 2005, there was a marked and broad expansion in antidepressant treatment in the United States, with persisting low rates of treatment among racial/ethnic minorities. During this period, individuals treated with antidepressants became more likely to also receive treatment with antipsychotic medications and less likely to undergo psychotherapy.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.0
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据